161 - 2022 CCS GUIDELINE FOR USE OF GLP-1 RECEPTOR AGONSISTS AND SGLT2 INHIBITORS FOR CARDIORENAL RISK REDUCTION IN ADULTS

Thursday, October 27, 2022

3:15 PM – 4:15 PM EDT

Location: Canada Hall 1

Target Audience: Clinical cardiologists, General: All cardiovascular (clinical and research) health professionals, Trainee (clinical)

Co-Chair(s)

G B John Mancini, MD, FRCP (C), FACP, FACC

Professor of Medicine, University of British Columbia
University of British Columbia
Vancouver, British Columbia, Canada
Eileen O'Meara

Cardiologist
Montreal Heart Institute
Université de Montréal
Montreal, Quebec, Canada

At the conclusion of this session, participants will be able to:

understand the role of novel diabetes agents for reducing risk of MACE
understand the role of novel diabetes agents for reduction of progression of renal disease
understand the role of novel diabetes agents for reduction of CV Death and hospitalization for HF
understand common cautions and contraindications for use of novel diabetes agents
understand how to integrate novel diabetes agents into cardiovascular practice
understand how to become a member of a multidisciplinary effort to enhance patient outcomes and quality of life when using novel diabetes agents